LX3305 250 mg capsule ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
161Familial benign chronic pemphigus1

161. Familial benign chronic pemphigus


Clinical trials : 5 Drugs : 9 - (DrugBank : 4) / Drug target genes : 2 - Drug target pathways : 24
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000373-80-FR
(EUCTR)
24/05/201813/03/2018A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or Hailey-Hailey DiseaseA Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or Hailey-Hailey Disease - DERM-101 Darier’s Disease or Hailey-Hailey Disease
MedDRA version: 20.0;Level: LLT;Classification code 10011860;Term: Darier's disease;System Organ Class: 100000004850
MedDRA version: 20.1;Classification code 10019029;Term: Hailey-Hailey disease;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: LX3305 250 mg capsule
Product Code: LX3305
INN or Proposed INN: None
Other descriptive name: (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime
Dermecular Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 1;Phase 2France